Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Seer, Inc.NASDAQ: SEER

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $429K fell 51.5% year over year, ahead of the -57.4% change in trailing-twelve-month other income / expenses. Sequentially, it fell 72.3% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.

Context

  • Other income / expenses amounted to 31.3% of revenue in FY2025, down 66.2 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -51.5% holds above the trailing-twelve-month pace of -57.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$429K-72.3% QoQ
Last fiscal yearDec 2025
$5.05M-62.9% YoY
LTMMar 2026
$4.27M-57.4% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-51.5%——
1 year-62.9%——
3-year CAGR-0.2%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
5.05M USD
Year-over-year change
-62.9%
4-year CAGR
+76.0%

Other Income / Expenses vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -57.4% is the 14th highest of 19, against a peer median of -29.7%.
  • Other income / expenses amounts to 28.4% of revenue for SEER, versus a peer median of 47.9%.
SEER Competitors
Other Income / Expenses for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$50.31M USD+38.1%+80.3%47.9%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$21.22M USD+72.6%+111.8%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$19.31M USD-36.3%+48.3%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$18.56M USD-20.1%+84.3%2.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$16.4M USD+41.5%+55.1%38.2%
NKTXNkarta, Inc.LTM Mar 2026$16.38M USD-21.0%+49.6%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$14.69M USD+6.7%+72.3%—
PHVSPharvaris N.V.LTM Sep 2026€14.39M EUR+118.3%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026$10.16M USD-24.2%—29.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$5.44M USD-67.9%-1.8%19.3%
SEERSeer, Inc.LTM Mar 2026$4.27M USD-57.4%-0.2%28.4%
PEPGPepGen Inc.LTM Mar 2026$4.08M USD-37.0%+11.3%—
STTKShattuck Labs, Inc.LTM Mar 2026$2.79M USD-35.2%+24.9%279.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$2.57M USD-45.0%+31.0%—
MNOVMediciNova, Inc.LTM Mar 2026$1.2M USD-24.3%+31.9%201.5%
SANASana Biotechnology, Inc.LTM Mar 2026-$4.43M USD-212.0%——
MOLNMolecular Partners AGLTM Mar 2026-CHF 6.37M CHF-427.8%——
QSIQuantum-Si incorporatedLTM Mar 2026-$7.6M USD-178.5%—410.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$54.54M USD-309.6%—175948.4%
Peer median (excluding SEER) —-29.7%+49.0%47.9%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.